Cargando…

Medical Therapy for Heart Failure with Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) is a challenging disease state that has long been plagued by heterogeneity in diagnostic criteria and underlying etiologies. Due in part to the complexity of defining this disease and the simplistic approach of only studying medications that hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnado, Sara, Ali, Hyeon-Ju Ryoo, Trachtenberg, Barry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Houston Methodist DeBakey Heart & Vascular Center 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733121/
https://www.ncbi.nlm.nih.gov/pubmed/36561091
http://dx.doi.org/10.14797/mdcvj.1162
_version_ 1784846292341489664
author Varnado, Sara
Ali, Hyeon-Ju Ryoo
Trachtenberg, Barry
author_facet Varnado, Sara
Ali, Hyeon-Ju Ryoo
Trachtenberg, Barry
author_sort Varnado, Sara
collection PubMed
description Heart failure with preserved ejection fraction (HFpEF) is a challenging disease state that has long been plagued by heterogeneity in diagnostic criteria and underlying etiologies. Due in part to the complexity of defining this disease and the simplistic approach of only studying medications that have shown significant improvement in heart failure with reduced ejection fraction, there have been a multitude of negative trials in this population. In the past few years, however, there have been medications that have finally shown to benefit patients with HFpEF. In particular, the blockbuster class of medications called SGLT2 inhibitors have provided a treatment option that improves outcomes in this group of patients. There is increasing focus on HFpEF research that aims to improve the phenotyping of these patients to more successfully tailor therapy and improve patient outcomes.
format Online
Article
Text
id pubmed-9733121
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Houston Methodist DeBakey Heart & Vascular Center
record_format MEDLINE/PubMed
spelling pubmed-97331212022-12-21 Medical Therapy for Heart Failure with Preserved Ejection Fraction Varnado, Sara Ali, Hyeon-Ju Ryoo Trachtenberg, Barry Methodist Debakey Cardiovasc J Review Heart failure with preserved ejection fraction (HFpEF) is a challenging disease state that has long been plagued by heterogeneity in diagnostic criteria and underlying etiologies. Due in part to the complexity of defining this disease and the simplistic approach of only studying medications that have shown significant improvement in heart failure with reduced ejection fraction, there have been a multitude of negative trials in this population. In the past few years, however, there have been medications that have finally shown to benefit patients with HFpEF. In particular, the blockbuster class of medications called SGLT2 inhibitors have provided a treatment option that improves outcomes in this group of patients. There is increasing focus on HFpEF research that aims to improve the phenotyping of these patients to more successfully tailor therapy and improve patient outcomes. Houston Methodist DeBakey Heart & Vascular Center 2022-12-06 /pmc/articles/PMC9733121/ /pubmed/36561091 http://dx.doi.org/10.14797/mdcvj.1162 Text en Copyright: © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Varnado, Sara
Ali, Hyeon-Ju Ryoo
Trachtenberg, Barry
Medical Therapy for Heart Failure with Preserved Ejection Fraction
title Medical Therapy for Heart Failure with Preserved Ejection Fraction
title_full Medical Therapy for Heart Failure with Preserved Ejection Fraction
title_fullStr Medical Therapy for Heart Failure with Preserved Ejection Fraction
title_full_unstemmed Medical Therapy for Heart Failure with Preserved Ejection Fraction
title_short Medical Therapy for Heart Failure with Preserved Ejection Fraction
title_sort medical therapy for heart failure with preserved ejection fraction
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733121/
https://www.ncbi.nlm.nih.gov/pubmed/36561091
http://dx.doi.org/10.14797/mdcvj.1162
work_keys_str_mv AT varnadosara medicaltherapyforheartfailurewithpreservedejectionfraction
AT alihyeonjuryoo medicaltherapyforheartfailurewithpreservedejectionfraction
AT trachtenbergbarry medicaltherapyforheartfailurewithpreservedejectionfraction